Immupharma Regulatory News (IMM)

FOR IMMEDIATE RELEASE 11 July 2012

RNS REACH

ImmuPharma PLC

Voted Best Medical Research and Development Company, Europe 2012

ImmuPharma PLC (LSE: IMM) ("ImmuPharma" or the "Company"), the specialist discovery and development pharmaceutical company, has been voted "Best Medical Research and Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2012.

This is the second time ImmuPharma has won this prestigious award, the first being in 2010 when voted "Best Drug Development Company, Europe".

The Awards have today been published in the Summer edition of "The New Economy", viewable online at www.theneweconomy.com/awards/healthcare-awards-2012.

To view the interview with Dimitri Dimitriou, Chief Executive Officer of ImmuPharma, please go to the "Investors Page" of ImmuPharma's website (www.immupharma.com) where you will see the link under "Interviews".

For further information please contact:

Notes to Editors

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company's most advanced drug candidate, LupuzorTM a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation. ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com